EB1010 / Enterome, Nestle - LARVOL DELTA

EB1010, a putative Christensenellaceae-derived microbial peptide, exhibits anti-inflammatory activity and therapeutic potential in ulcerative colitis. (PubMed, Gut Microbes) - "EB1010 was well tolerated in a 4-week rat toxicology study, with no adverse effect observed at doses up to 1.5 mg/kg/d by intravenous administration. These findings position EB1010 as a safe, locally acting, microbiota-derived peptide with potential therapeutic applications."

Journal • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease • Ulcerative Colitis

Enterome signs major strategic R&D collaboration with Nestlé Health Science to develop and commercialize new AllerMimics and EndoMimics immunotherapies for food allergies and inflammatory bowel disease (PRNewswire) - "Enterome and Nestlé Health Science will co-develop Enterome's lead EndoMimics™ compound, EB1010, a potent local inducer of IL-10 targeting food allergies and inflammatory bowel disease (IBD). EB1010 is due to enter clinical trials in 2023. The collaboration will also create a pipeline of novel AllerMimics™ candidates that mimic food allergens to generate immune tolerance and identify new EndoMimics™ that reduce inflammation caused by food allergies."

Licensing / partnership • New trial • Immunology • Inflammatory Bowel Disease

Enterome to present significant progress with its OncoMimics pipeline at Jefferies London Healthcare Conference (PRNewswire) - "EB1010, a new orally delivered bioactive and a potent local inducer of IL-10, which has been selected to provide improved therapeutic outcomes for patients with inflammatory bowel disease (IBD). EB1010 is expected to enter clinical trial in 2023."

New trial • Immunology • Inflammatory Bowel Disease